28results about "Polypeptide with affinity tag" patented technology

The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and / or protein mixtures.

The present disclosure relates to novel cell wall binding domains, enzymatically active domains, and chimeric cell wall hydrolases with anti-Cutibacterium acnes activity. The disclosure also relates to compositions comprising these, and uses thereof in the treatment of conditions associated with Cutibacterium acnes.

Compositions, methods, and kits for performing multiplexed, spatially resolved, or single-cell chromatin analysis are provided.

Hypersensitive response eliciting peptides exhibiting improved solubility, stability, resistance to chemical degradation, or a combination of these properties are disclosed. Also disclosed are uses of these peptides or fusion polypeptides or DNA constructs encoding the same for modulating plant biochemical signaling, conferring disease resistance to a plant, enhancing plant growth, conferring tolerance to a plant to a biotic stress, conferring tolerance and resistance to a plant to an abiotic stress, conferring desiccation resistance to a cutting taken from an ornamental plant, conferring postharvest disease resistance or postharvest desiccation resistance to a fruit or vegetable, or enhancing the postharvest life of a fruit or vegetable.

The present invention relates to genetically encoded cellular iron biosensors, in particular to nucleic acids encoding the same, vectors and cells comprising the nucleic acid(s), in vitro methods for measuring, and optionally monitoring, cellular Fe2+ and / or cellular iron-sulfur cluster (ISC), in vitro screening methods for a compound that affects cellular Fe2+ and / or cellular ISC, and to in vitro methods for identifying a dosage and / or formulation of a compound that affects cellular Fe2+ and / or cellular ISC.

A variant polypeptide of fructanase, a fusion protein and an enzyme composition comprising said variant polypeptide, recombinant host cell producing the variant polypeptide, method for manufacturing the variant polypeptide, a use of the variant polypeptide to degrade and modify fructan containing material, and a premix for baking comprising the variant polypeptide.

Disclosed are blocking peptides and related methods, formulations, and compositions, pertaining to the field of biomedicine. Based on the regulatory mechanism by which the negative regulator TGF-β modulates the transport and degradation of STING, the use of AP3D1 as a drug target for in vitro screening of blocking agents is provided to identify the S9 regulatory site and the R26 regulatory site of AP3D1. Corresponding blocking peptides targeting the S9 regulatory site and the R26 regulatory site, respectively, were synthesized to specifically inhibit AP3D1-mediated inactivation of STING signaling by tumor microenvironment factors, thereby blocking at least one of the S9 regulatory site and the R26 regulatory site and effectively restricting STING transport and degradation. The blocking peptide can synergize with various treatment modalities, including chemotherapy, radiotherapy, PARP inhibitors, and STING agonists, significantly enhancing cGAS-STING signaling activation in tumors during therapy and achieving more potent antitumor efficacy.

The present disclosure relates generally to compositions comprising variant granulocyte macrophage-colony-stimulating factor (GMCSF) fusion polypeptides that are configured to bind to a tumor extracellular matrix (ECM) component, and methods for using the same to treat solid tumors.

Provided is a HER2 binding polypeptide comprising the amino acid sequence of SEQ ID NO: 1. Also provided is a radiolabeled polypeptide comprising a radioactive chelate of a HER2 binding polypeptide and a radionuclide. Also provided are methods and uses of the polypeptide in therapeutic, diagnostic and prognostic applications, for example relating to cancers characterized by overexpression of HER2.

Disclosed herein are vectors that include alphavirus-based expression platforms. Also disclosed are methods associated with the alphavirus-based expression platforms and co-administration of an inhibitor of Type I interferon signaling.

The present disclosure related to variant polypeptides having intein activity, for example, controllable splicing and / or N-terminal cleavage, fusion proteins, comprising the variants, systems comprising the polypeptides or fusion proteins, and related kits and processes. The variants, fusion proteins, and systems can be used for a variety of applications in which intein splicing and / or N-terminal cleavage is desirable, for instance, intein-based protein expression and purification.

The present disclosure provides systems and methods for transposing a cargo nucleotide sequence into a target nucleic acid site. These systems and methods may comprise a double-stranded nucleic acid comprising the cargo nucleotide sequence, wherein the cargo nucleotide sequence is configured to interact with a recombinase complex, an effector complex comprising an effector and at least one engineered guide polynucleotide configured to hybridize to the target nucleic acid site, and the recombinase complex wherein said recombinase complex is configured to recruit the cargo nucleotide to the target nucleic acid site.

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and / or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Described herein are fusion proteins, as well as compositions and systems comprising the fusion proteins. Also described herein are methods of using and / or producing the fusion proteins, such as methods of using the fusion proteins to modify or edit a target nucleic acid.

Provided herein are mRNAs encoding masked proteins for use in the treatment of diseases. More specifically, provided herein are mRNAs encoding masking proteins having a therapeutic protein, a masking moiety, at least one cleavable moiety, and, optionally, a half life extending moiety, with the at least one cleavable moiety that is inert in the liver and spleen, and the therapeutic protein is activated upon cleavage of the at least one cleavable moiety in a target tissue, such as a tumor tissue or infection site, aside from the liver or spleen.

The present invention pertains to a novel sealant, glue or filler for biological tissues based on a biodegradable, cross-linkable fusion protein having the formula (I) ULD-(L)n-ULD, wherein ULD is an ubiquitin-like-domain, forming tetrameric protein structures, and (L) is a linker sequence, preferably a peptide or protein sequence having 5-2500 aa. The particular advantage of the current system lies in its great variability and low toxicity towards the recipient biological tissue, preferably a mammalian, e.g. a human, or any animal species. Moreover, the novel tissue sealant allows providing sealants, glues or fillers with high elasticity, adhesiveness and high resistance, which can be applied to a (wet) biological tissue within minutes. The present invention also pertains to medical uses of the novel biological tissue sealant, glue or filler and to methods of treatment using the same.

The present application provides activatable proprotein homodimers comprising at least two separate polypeptide chains, each chain comprising an IL-2 protein, a cleavable linker, and an IL-2 binding protein, and other optional features, related pharmaceutical compositions, and methods of use thereof.

A variant polypeptide of fructanase, a fusion protein and an enzyme composition comprising said variant polypeptide, recombinant host cell producing the variant polypeptide, method for manufacturing the variant polypeptide, a use of the variant polypeptide to degrade and modify fructan containing material, and a premix for baking comprising the variant polypeptide.

The present invention is directed to a peptide, wherein said peptide has an amino acid sequence according to SEQ ID N° 1. The current invention also discloses compositions comprising said peptide, as well as specific uses.

Polypeptides and uses thereof are provided. The polypeptide includes an N-terminal sequence and a C-terminal sequence, wherein the N-terminal sequence includes one or more repeating units including the amino acid sequence shown in SEQ ID NO. 1. The use of a human structural material for tissue filling and augmentation is provided in the present disclosure, which is expected to have a wide range of applications in the fields such as breast augmentation, rhinoplasty and mid-face filling as it does not require transplantation from the human body, yet has the natural advantages of using human tissue for filling.